[1]Jacot W, Im SA, Loi S, et al. Exploratory biomarker analysis of Trastuzumab deruxtecan (TDXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic brea...
在过去 HER2靶向治疗成果的基础上,对这些新概念的研究和这些方法的使用将最终导致持续的进展。 参考文献:1.Sandra M. Swain, Mythili Shastry & Erika Hamilton Targeting HER2-positive breast cancer: advances and future directions Nature Reviews Drug Discovery(2022)...
在临床中实施这些复杂的治疗策略之前,需要识别出可以从不同治疗策略中获益的人群和生物标志物,这也是以后的研发方向。 Swain Sandra M,Shastry Mythili,Hamilton Erika. Targeting HER2-positive breast cancer: advances and future directions.[J]. Nature rev...
Breast cancer is a leading cause of malignancy-related death in women. The prognosis for patients with breast cancer is determined by well established pathologic features associated with poor outcome such as histological grade, tumor size, and node involvement. The proto-oncogene HER2/neu or its ...
HER-2 是一种跨膜生长因子受体,由人类的HER2/neu基因编码,与 HER1 (EGFR)、HER3 和 HER4 一起属于 HER 家族蛋白。EGF 相关的生长因子中的任何一个与 HER1、HER3 或 HER4 结合会诱导HER受体二聚化,随后激活酪氨酸激酶胞内结构域,从而触发许多不同的下游途径。[1] ...
【Clinicaland molecular characteristics of HER2-low-positive breast cancer】 HER2低表达原发肿瘤体积比HER2无表达(IHC-)者大,更易出现淋巴结转移,且对新辅助化疗(NAC)的反应较差。早期一项大型前瞻性研究显示,HER2 IHC 2+、FISH阴性的乳腺癌患者往往表现为肿瘤体积大、组织学分级高、腋窝淋巴结受累、Ki-67增殖指...
The phase III TH3RESA trial randomized ∼600 patients with advanced HER2-positive breast cancer, previously treated with at least two HER2-directed therapies (including trastuzumab and lapatinib) in a 2 : 1 ratio to T-DM1 or physician’s choice of treatment (HER2-targeted regimens for ...
[10]Gullo G,Bettio D,Torri V,Masci G,Salvini P,Santoro A.Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.Investig N Drugs.2009;27:179–83. ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
HER2-positive breast cancer Biomarkers Metastatic breast cancer Targeted therapy Introduction Human epidermal growth factor receptor-2 (HER2) is overexpressed in 15–20% of breast cancer (BC) cases, resulting in an aggressive clinical behaviour [1]. The introduction of trastuzumab has contributed to ...